Compugen (CGEN) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Compugen Ltd. has secured a new U.S. patent for its innovative cancer treatment approach, involving the combination of its COM902 antibody with anti-PD-1 and anti-PVRIG antibodies. This patent strengthens Compugen’s intellectual property portfolio in the field of DNAM-1 axis checkpoint inhibitors, potentially enhancing shareholder value. The patent is part of Compugen’s strategy to develop advanced cancer immunotherapies and is valid until at least 2037.
For further insights into CGEN stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- M&A News: Blackrock to Buy HPS for $12B to Fortify Alternative Investments Business
- Google Urges Appeals Court to Overturn App Store Change Ruling
- Symbotic Craters 36% on Financial Misstatements and 10-K Filing Delay
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
